Amylyx Pharmaceuticals, Inc. (AMLX) · Sep 8, 2026 · Material agreement

Amylyx locks in avexitide manufacturing, taking $30M pre-approval capacity risk

Dual-source manufacturing — $30M upfront capacity fee; minimum annual purchases beginning in 2028

Amylyx secures two commercial avexitide suppliers, but commits $30M upfront and minimum purchases before regulatory approval.

Commercial readiness was expected; the contracts are the new information. Amylyx had already positioned avexitide for potential commercialization if approved, so securing manufacturing capacity is directionally consistent with the standing plan rather than a wholly unexpected strategic pivot. The filing now turns that plan into concrete supplier commitments: Bachem and Polypeptide will supply avexitide drug substance for commercial use, if approved. 〔0〕

ItemFiling terms
SuppliersBachem and Polypeptide; both non-exclusive
Bachem commitmentFive-year initial term, renewing in three-year periods; minimum annual purchases beginning in 2028
Polypeptide commitment$30 million upfront capacity-reservation fee; minimum annual purchases beginning in 2028
PricingBachem pricing adjusts annually for labor, utilities and overhead; Polypeptide pricing is volume-based and may also adjust annually
Approval statusCommitments apply to commercial supply if avexitide is approved

The positive is supply de-risking, not improved clinical odds. Two non-exclusive manufacturers give Amylyx more than one commercial source and provide capacity planning ahead of a potential launch. The Bachem agreement begins with a five-year term, while the Polypeptide arrangement remains only a term sheet pending a definitive agreement. 〔1〕

The trade-off is meaningful pre-approval cash and purchase exposure. Amylyx must pay Polypeptide $30 million for capacity reservation and accept minimum annual purchase requirements beginning in 2028, even though regulatory approval is not yet secured. The filing does not disclose the minimum volumes, supply prices, or total future purchase obligations, so the economic burden cannot yet be fully assessed.

Net read: strategically sensible, but not an unqualified positive surprise. The agreements reduce a potential manufacturing bottleneck if avexitide succeeds, but they also lock in capital and volume commitments before approval and before the Polypeptide contract is final. With no clean consensus benchmark for a supply agreement, this lands as a mixed event: operationally constructive, financially and commercially conditional.

What to watch next

Definitive Polypeptide agreement in Q3 10-Q

Original filing on SEC EDGAR

More Amylyx Pharmaceuticals, Inc. news

Amylyx locks in avexitide manufacturing, taking $30M pre-approval capacity risk | AMLX Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.